A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework
Sadatsafavi M, Marra C, Marra F, Moran O, Fitzgerald JM, Lynd L

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.jval.2012.09.006

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Age Factors; Algorithms; Antitubercular Agents /adverse effects /therapeutic use; BCG Vaccine /administration & dosage; Canada; Contact Tracing; Decision Support Techniques; Emigrants and Immigrants /statistics & numerical data; Health Policy; Humans; Isoniazid /adverse effects /therapeutic use; Latent Tuberculosis /drug therapy; Models, Theoretical; Practice Guidelines as Topic; Quality-Adjusted Life Years; Registries; Risk Assessment /methods; Time Factors; Tuberculin Test; Young Adult

AccessionNumber
22013007937

Date bibliographic record published
15/03/2013